je.st
news
Tag: merck
Merck Sues Actavis Unit Over Patent for Generic NuvaRing
2013-12-25 00:26:03| Biotech - Topix.net
Merck & Co. sued Actavis Plc's Warner Chilcott unit seeking to block sales of a generic version of NuvaRing, a contraceptive with estimated annual sales of more than $664 million.
Tags: unit
patent
generic
merck
Merck Announces Launch of a New Business Focused on Comprehensive, Evidence-Based Weight Management Interventions in the U.S.
2013-12-20 15:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a new business focused on providing comprehensive, evidence-based weight management interventions for employers, hospitals, medical groups, health plans and patients. Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
us
business
management
Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma
2013-12-18 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the companys investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKlines orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
combination
evaluate
Merck Wins Over FDA Panel With New Allergy Drug
2013-12-15 12:08:13| Biotech - Topix.net
Merck received word from the U.S. Food & Drug Adminstration that Grastek, an orally administered grass allergy remedy, was both safe and effective for allergy sufferers, according to a report by Reuters .
Merck KGaA: Allergopharma Plans to Invest $55M in Production Facility
2013-12-13 16:37:09| Biotech - Topix.net
The German pharmaceutical, chemical and life science company Merck KGaA, Darmstadt, Germany, broke ground today on a new production facility for its Allergopharma unit in Reinbek near Hamburg.
Tags: production
plans
facility
invest
Sites : [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] next »